Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Plain-language summary
This trial is testing Mogamulizumab for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Mogamulizumab (DRUG): Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle. | LD TSEBT (RADIATION): Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
Mogamulizumab, LD TSEBT
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details